References: Malignant mesothelioma detailed guide

References: Malignant mesothelioma

detailed guide

American Joint Committee on Cancer. Pleural mesothelioma. AJCC Cancer Staging

Manual. 7th ed. New York, NY: Springer; 2010: 271-274.

Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF,

Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS,

Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2009, National Cancer

Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009/, based on November 2011

SEER data submission, posted to the SEER web site, April 2012.

Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic cell-based

immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit

Care Med. 2010;181:1383-1390.

National Cancer Institute. Physician Data Query (PDQ). Malignant Mesothelioma:

Treatment. 2012. Accessed at

www.cancer.gov/cancertopics/pdq/treatment/malignantmesothelioma/HealthProfessional

on August 2, 2012.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines

in Oncology: Malignant Pleural Mesothelioma. V.2.2012. Accessed at

www.nccn.org/professionals/physician_gls/pdf/mpm.pdf on August 2, 2012.

Pan X, Day W, Wang W, et al. Residential proximity to naturally occurring asbestos and

mesothelioma risk in California. Am J Resp Crit Care. 2005;172:1019-1025.

Pass HI, Vogelzgang NJ, Hahn SM, Carbone M. Benign and malignant mesothelioma. In:

DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's

Cancer: Principles and Practice of Oncology . 9th ed. Philadelphia, Pa: Lippincott

Williams & Wilkins; 2011:2052-2080.

Price B, Ware A. Mesothelioma trends in the United States: An update based on

Surveillance Epidemiology and End Results program date for 1973-2003. Am J

Epidemiol. 2004;159:107-112.